Source: Virtual Congress 2021 – COVID-19 and management of lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Kagawa (Aichi, Japan), T. Uemura (Aichi, Japan), M. Horiuchi (Aichi, Japan), S. Fukuda (Aichi, Japan), K. Maeno (Aichi, Japan), T. Oguri (Aichi, Japan), N. Takeda (Aichi, Japan), K. Fukumitsu (Aichi, Japan), T. Tajiri (Aichi, Japan), H. Ohkubo (Aichi, Japan), Y. Ito (Aichi, Japan), A. Niimi (Aichi, Japan). Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer. 3855

Member's Comments

No comment yet.

Related content which might interest you: Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017 Year: 2018 Targeted therapy in non-small cell lung cancer Source: Breathe 2012; 8: 206-215 Year: 2012 Second-line therapy in elderly patients with advanced nonsmall cell lung cancer Source: Eur Respir J 2014; 43: 240-249 Year: 2004 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011 Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease. Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009 Radiotherapy in the treatment of nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 207–243 Year: 2009 Surgical treatment of nonsmall cell lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=170 Year: 2001 Chemotherapy in advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 271–283 Year: 2009 Radio(chemo)therapy in locally advanced nonsmall cell lung cancer Source: Eur Respir Rev 2015; 25: 65-70 Year: 2016 Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study Source: ERJ Open Res, 6 (1) 00189-2019; 10.1183/23120541.00189-2019 Year: 2020 Proliferative activity of non-small cell lung cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005 Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Effect of comorbidity on the prognosis of non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006